Regulatory Affairs
PCN Rejects Kano Taskforce’s Drug Trade Allegations, Defends Pharmaceutical Licensing in Residential Areas, Reports 6,838 Outlets Sealed in 2026
The Pharmacy Council of Nigeria has rejected allegations that it shielded illicit drug dealers in Kano State, defended its authority over pharmaceutical premises licensing, clarified NAFDAC’s role in product import permits and disclosed that 6,838 pharmaceutical outlets were sealed during enforcement operations across 11 states in 2026.
The Pharmacy Council of Nigeria (PCN) has strongly rejected allegations by the Chairman of the Kano State Multi-Agency Taskforce on Drug Abuse and Illicit Trafficking, Barrister Muhuyi Magaji Rimin Gado, accusing the Council of shielding drug dealers and facilitating the distribution of illicit substances in Kano State.
In a four-page press release dated 14 November 2026, the Council described the allegations as unsubstantiated and defended its regulatory procedures, including the registration of pharmaceutical premises in residential areas, its licensing responsibilities and its enforcement activities across the country.
The response followed a press conference held by the Kano State taskforce chairman, during which he accused the PCN and the National Agency for Food and Drug Administration and Control (NAFDAC) of enabling illicit pharmaceutical distribution through regulatory approvals and alleged misconduct by some officials.
The allegations also questioned the circumstances surrounding the issuance of import licences to pharmaceutical companies dealing in pregabalin, particularly following its scheduling as a controlled drug by NAFDAC on 14 September 2026.
PCN Rejects Allegations of Shielding Drug Dealers
The Council disputed claims that it had facilitated unlawful pharmaceutical activities by registering a pharmaceutical premises at No. 10 Apple Avenue, which the taskforce chairman reportedly described as a residential location allegedly used as a concealed distribution outlet.
According to the PCN, its Pharmaceutical Premises Location, Inspection, Structure, Monitoring and Enforcement Regulations, 2022, do not prohibit the registration of pharmaceutical premises in residential areas.
The Council maintained that both residential and commercial locations are eligible for registration, provided the facilities satisfy the applicable regulatory requirements.
It further argued that determining whether a property allocated for residential purposes can be used for pharmaceutical business is not within the PCN's mandate when considering an application for premises registration.
The Council therefore rejected the allegation that registering the premises amounted to facilitating unlawful activities, describing the accusation as lacking supporting evidence.
PCN Clarifies Import Licensing Responsibilities Between PCN and NAFDAC
Addressing concerns about the importation of pregabalin and other pharmaceutical products, the PCN clarified the distinction between its responsibility for issuing import licences to importing companies and NAFDAC's responsibility for granting product permits.
The Council stated that issuing import licences to pharmaceutical importing companies falls within its regulatory mandate, while the authority to issue permits for importing specific products and determining their quantities rests with NAFDAC.
It argued that the issuance of an import licence should not, by itself, be interpreted as evidence of regulatory wrongdoing, unless there is evidence of illegal distribution of the product from the premises concerned.
The clarification highlights the distinction between the regulatory approval of an importing company and authorisation to import a particular medicine.
PCN Defends Its Regulatory Structure and Enforcement Capacity
The Council also rejected suggestions that its limited number of personnel had affected its ability to regulate pharmaceutical premises effectively.
It explained that pharmaceutical premises inspection and licensing involve two established committees: the Pharmaceutical Inspection Committee (PIC) and the Patent and Proprietary Medicines Vendors Licence Committee (PPMVLC).
According to the PCN, the committees are chaired by Directors of Pharmaceutical Services in the respective State Ministries of Health, while PCN officers serve as inspectors alongside other experienced pharmacists appointed at state level.
The Council further explained that its State Officers-in-Charge serve as secretaries to the committees, providing administrative and secretariat support rather than exercising exclusive authority over premises licensing decisions.
It maintained that this arrangement enables the Council to mobilise the necessary personnel for regulatory activities, irrespective of the number of officers permanently stationed in a particular state.
The PCN also cited Nigeria's achievement of World Health Organization Global Benchmarking Tool Maturity Level 3, stating that it and NAFDAC are the only regulatory agencies in Africa to have achieved and retained this ranking.
PCN Reports 6,838 Pharmaceutical Outlets Sealed in 2026
Providing figures on its enforcement activities, the Council disclosed that its National Enforcement Team had visited 11 states in 2026, with Kano State visited twice, in April and September.
According to the press release, the operations recorded the following:
• 9,908 pharmaceutical outlets visited across the 11 states.
• 6,838 outlets sealed for various offences.
• 2,304 outlets visited in Kano State.
• 1,631 outlets sealed in Kano State.
• 15 investigations ongoing in Kano State.
The Council clarified that these figures do not include routine enforcement activities conducted by its state offices.
The figures were presented as evidence of the Council's continued regulatory activities and efforts to address non-compliance within the pharmaceutical sector.
Council Explains Purpose of Coordinated Wholesale Centres
The PCN also addressed the taskforce chairman's criticism of the Coordinated Wholesale Centre (CWC) initiative, which he reportedly accused the Council of compromising through the registration of pharmaceutical premises outside the designated wholesale centre.
The Council explained that the CWC programme was developed by the Federal Government through the Federal Ministry of Health and Social Welfare and implemented by the PCN to address the problem of open drug markets.
According to the Council, the initiative is specifically designed to relocate identified and verified pharmaceutical vendors operating in open drug markets, including Sabon Gari and other identified clusters in Kano State.
It stressed that the initiative does not prevent independent pharmaceutical wholesalers, distributors, importers and warehouse operators from establishing separate facilities for their businesses.
The Council further disclosed that CWC development was ongoing in Lagos, Anambra and Imo States, while Abia, Kaduna, Oyo and Gombe had received approvals but were yet to commence development.
PCN Invites Evidence of Alleged Staff Misconduct
On allegations that some PCN personnel were involved in clandestine pharmaceutical businesses and illicit drug distribution, the Council challenged the taskforce chairman to provide specific evidence.
It stated that the chairman had not identified any staff members or provided documented cases to substantiate the allegations.
The Council maintained that it takes allegations of misconduct against its personnel seriously and is willing to investigate credible reports involving its officers or registered pharmaceutical premises.
It also called on regulated stakeholders, staff members and members of the public to report suspected wrongdoing through its dedicated reporting channels.
Controlled Medicines Monitoring and Public Safety
The Council reiterated its commitment to monitoring the distribution of controlled medicines through regulatory mechanisms, including the use of Form K (Disposal of Poison Records).
It explained that pharmaceutical premises, including hospitals, are expected to maintain records of controlled substances sold, distributed or dispensed, with appropriate sanctions available where negligence or non-compliance is established.
The PCN also highlighted its collaboration with the United Nations Office on Drugs and Crime (UNODC), NAFDAC and other stakeholders to strengthen compliance with controlled-medicine distribution requirements.
The Council concluded that tackling illicit drug distribution and the unauthorised use of controlled medicines requires cooperation among regulatory institutions, law enforcement agencies, pharmaceutical stakeholders and the public.
It warned against allowing the fight against drug abuse to become an avenue for unfounded accusations or the undermining of established regulatory institutions.
Implications for Pharmacy Practice and Drug Regulation
The disagreement highlights important questions about the coordination of pharmaceutical regulation and drug-control enforcement in Nigeria.
While the PCN is responsible for regulating pharmaceutical premises and pharmacy practice, NAFDAC has responsibilities relating to the regulation and authorisation of medicines and other regulated products.
The allegations also raise questions about how regulatory agencies monitor the movement of controlled medicines from importation through wholesale distribution to dispensing.
For pharmacists and pharmaceutical businesses, the controversy reinforces the importance of maintaining appropriate documentation, complying with controlled-medicine requirements and ensuring that pharmaceutical premises operate within established regulatory frameworks.
Ultimately, allegations of regulatory misconduct should be investigated through transparent procedures, with credible evidence presented and appropriate accountability mechanisms applied.
SOURCE: Pharmacy Council of Nigeria (PCN), Rebuttal to Allegations by the Chairman Kano State Multi-Agency Taskforce on Drug Abuse and Illicit Trafficking, 14 November 2026.